U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07402070) titled 'IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer' on Jan. 16.
Brief Summary: This is a Phase 2 study to evaluate the safety, and efficacy of IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer.
Study Start Date: Feb. 04
Study Type: INTERVENTIONAL
Condition:
Resectable Stage II-III Non-small Cell Lung Cancer
Intervention:
DRUG: IBI363
Subjects will receive IBI363 for up to 4 cycles, each cycle is 21 days, the first treatment cycle is 28 days
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Disclaimer: Curated by HT Syndica...